Biosimilars in Inflammatory Bowel Disease.
Am J Gastroenterol
; 116(1): 45-56, 2021 01 01.
Article
em En
| MEDLINE
| ID: mdl-33110013
ABSTRACT
Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-α has become a cornerstone of treatment of patients with inflammatory bowel disease. Although clinically effective, the biological therapies remain expensive, and their availability and utilization have been at times limited due to their high costs. Biosimilars are biological products similar to but not identical to the original biological agent or "reference biologic," also called "originator biologic." It is hoped that the use of biosimilars might enable these agents to become more available and, thus, decrease further expenditures related to the use of the original reference agents such as infliximab and adalimumab. In this study, we review the currently available evidence and shortcomings of these data supporting the use of biosimilars for the treatment of patients with inflammatory bowel disease, including their efficacy and safety as related to initiating therapy with biosimilar agents or switching between reference and biosimilar biologic agents.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Inflamatórias Intestinais
/
Medicamentos Biossimilares
/
Inibidores do Fator de Necrose Tumoral
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article